Fidelity Investments
DSGN icon

Fidelity Investments’s Design Therapeutics DSGN Stock Holding History

Fidelity Investments’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Sell
776,462
-21,949
-3% -$274K ﹤0.01% 2073
2026
Q1 		$8.5M Buy
798,411
+27,143
+4% +$275K ﹤0.01% 2103
2025
Q4 		$7.23M Buy
771,268
+30,419
+4% +$238K ﹤0.01% 2153
2025
Q3 		$5.58M Sell
740,849
-210,349
-22% -$1.05M ﹤0.01% 2205
2025
Q2 		$3.21M Buy
951,198
+3,148
+0.3% +$11.8K ﹤0.01% 2321
2025
Q1 		$3.66M Sell
948,050
-3,832
-0.4% -$18.3K ﹤0.01% 2258
2024
Q4 		$5.87M Buy
951,882
+123,217
+15% +$713K ﹤0.01% 2100
2024
Q3 		$4.46M Buy
828,665
+747,649
+923% +$3.52M ﹤0.01% 2164
2024
Q2 		$271K Buy
81,016
+2,675
+3% +$10.4K ﹤0.01% 2934
2024
Q1 		$316K Sell
78,341
-671
-0.8% -$1.79K ﹤0.01% 2867
2023
Q4 		$209K Buy
79,012
+8,954
+13% +$20.5K ﹤0.01% 2952
2023
Q3 		$165K Sell
70,058
-567,712
-89% -$2.65M ﹤0.01% 2945
2023
Q2 		$4.02M Sell
637,770
-320,133
-33% -$1.96M ﹤0.01% 2121
2023
Q1 		$5.53M Sell
957,903
-161,634
-14% -$1.21M ﹤0.01% 2060
2022
Q4 		$11.5M Buy
1,119,537
+36,675
+3% +$497K ﹤0.01% 1835
2022
Q3 		$18.1M Buy
1,082,862
+55,922
+5% +$1.11M ﹤0.01% 1645
2022
Q2 		$14.4M Sell
1,026,940
-426
-0% -$5.75K ﹤0.01% 1791
2022
Q1 		$16.6M Buy
1,027,366
+27,366
+3% +$419K ﹤0.01% 1870
2021
Q4 		$21.4M Hold
1,000,000
– – ﹤0.01% 1796
2021
Q3 		$14.7M Hold
1,000,000
– – ﹤0.01% 1967
2021
Q2 		$19.9M Hold
1,000,000
– – ﹤0.01% 1850
2021
Q1 		$29.9M Buy
+1,000,000
New +$33.7M ﹤0.01% 1620

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's DSGN Position: Q2 2026 in Review

Fidelity Investments reduced its Design Therapeutics (DSGN) stake by 2.7% in Q2 2026, selling an estimated $274K and leaving 776,462 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2073.

Fidelity Investments first reported a position in DSGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $29.9M in Q1 2021. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Fidelity Investments held 776,462 shares of Design Therapeutics worth $11.2M as of Q2 2026.
  • Fidelity Investments sold 21,949 Design Therapeutics shares in Q2 2026, an estimated $274K.
  • Design Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2073 holding.
  • Fidelity Investments first reported a position in Design Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Fidelity Investments's Design Therapeutics position peaked at $29.9M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.